Lv41
500 积分 2023-01-05 加入
In vivo CAR T cell generation to treat cancer and autoimmune disease
18天前
已完结
Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders
18天前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
1个月前
已完结
Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions
1个月前
已完结
Cytokines in inflammatory bowel disease
1个月前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
1个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
1个月前
已完结
Ocular surface repair using decellularized porcine conjunctiva
1个月前
已完结
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
2个月前
已完结
Pathophysiology of Inflammatory Bowel Diseases
2个月前
已完结
皖公网安备34019202002308
